Xenon names Tucker Kelly CFO with $540k salary, 225k options, 30k RSUs

Xenon Pharmaceuticals Inc.

Tucker Kelly appointed CFO effective Oct 15, 2025; replaces interim CFO Ian Mortimer who remains CEO.
Kelly's base salary $540k; eligible for annual incentive up to 45% of base.
Granted inducement option for 225k shares at $41.90 (Oct 15 close) vesting over 4 years.
Granted 30k RSUs vesting 25% annually over 4 years.
Kelly previously CFO of Deciphera, led commercial transition; will support azetukalner launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.